A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension.
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2013
At a glance
- Drugs Azilsartan; Candesartan cilexetil
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Takeda
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 01 Feb 2011 Actual initiation date Jul 2007 and actual end date Jul 2008 are addedd as reported by ClinicalTrials.gov.